Scisparc Ltd (SPRC) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2023 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Scisparc Ltd  (NASDAQ: SPRC)


Scisparc Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Scisparc Ltd's ROI in the fourth quarter of 2025?
Scisparc Ltd achieved a return on average invested assets (ROI) of 309.31 % in its fourth quarter of 2025 a new company high.

ROI has improved compared to 118.74% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 6 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 25.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Investment Change TTM -55.81 % -42.74 % -34.99 % 0.46 % 25.65 %
Y / Y Net Income Change TTM 113.56 % 126.97 % 126.97 % 126.97 % 126.97 %
Investment (TTM) in Millions 5 5 0 5 9
Return On Investment (TTM) 309.31 % 118.74 % 101.85 % 72.29 % 64 %
SPRC's Overall Ranking # 25 # # # #
Seq. Investment Change TTM -18.01 % -14.23 % -29.02 % -11.47 % 6.24 %
Seq. Net Income Change TTM 113.56 % 0 % 0 % 0 % 126.97 %
Net Income (TTM) in Millions 13 6 6 6 6

SPRC Company Profile >> Back to SPRC Roi Comparisons >> See Annual SPRC Return On Investment



Return On Investment SPRC's Ranking
Within: No.
Industry # 3
Sector # 7
Overall # 25

Return On Investment Statistics
High Average Low
309.31 %
115.21 %
40.19 %
(Dec 31 2025)   (Dec 31 2022)



  News about Scisparc Ltd Return on Investment ROI

SciSparcs Strategic Leap FDA Approval Signals New Hope for Tourette Syndrome Treatment

September 30, 2024

Overview of Recent DevelopmentsIn a significant advancement for the treatment of Tourette Syndrome (TS), SciSparc Ltd. a clinical-stage pharmaceutical company, has received FDA approval to initiate its pivotal Phase IIb clinical trial. This approval comes less than a month after the application was submitted, marking a swift and efficient response from regulatory authorities. Key Facts of the Approval1. FDA Green Light : SciSparc can now proceed with its Phase IIb clinical trial, a critical milestone in the drug development process that evaluates the efficacy and safety of its novel treatment option.

SciSparc Ltd FDA Sanctioned Phase IIb Clinical Trial for Tourette Syndrome Amid Financial Fluidity and Sectoral...

September 23, 2024

The undertaking of such a pivotal study posits SciSparc Ltd at the vanguard of neurological disorder treatments, demonstrating a confluence of scientific rigour and steadfast commitment to advancing human health. The anticipation surrounding this clinical trial is palpable, as it aims to address the unmet needs of those besieged by the relentless tics and involuntary behaviours characteristic of Tourette Syndrome.In a parallel narrative, it is germane to elucidate the company s fiscal vicissitudes as recently chronicled. SciSparc Ltd has reported a return on average invested assets (ROI) of 61.36% for the concluding stanza of the annum 2023. This figure, whilst commendable, modestly lags behind the company s historical mean ROI of 66.69%. An astute examination reveals that this enhancement in ROI, which saw ascension from a preceding 29.45% in the third quarter, is predominantly ascribed to the burgeonment in net income.

Navigating Financial Waters A Comprehensive Review of Scisparc Ltds Loan Advances and Investment Performance

September 11, 2024

In a rapidly evolving economic landscape, healthcare companies are under continuous scrutiny regarding their financial strategies and investment returns. Scisparc Ltd, a company that has recently been in the spotlight for its financial maneuvers, provides a pertinent case study following its recent loan agreements and performance reports. This article aims to balance an interpretation of Scisparc s financial activities with the broader implications for stakeholders in the pharmaceutical and healthcare sectors. Loan Advances to AutoMaxScisparc has advanced a total of $4.25 million to AutoMax under a Bridge Loan agreement, with the recent addition of a $1.85 million loan following AutoMax s direct import agreement with a major Chinese vehicle manufacturer. The decision to finance AutoMax reflects a strategic partnership intended to bolster AutoMax’s growth in the automotive sector, potentially leading to enhanced market presence and revenue opportunities.These financial maneuvers can be seen as a diversification strategy for Scisparc, signaling a proactive approach to capitalizing on emerging markets outside conventional pharmaceutical investments. However, this also raises questions regarding the company’s focus and commitment to its core healthcare initiatives. Stakeholders may view this venture as either a necessary expansion into a high-demand sector or a potential distraction from its pharmaceutical s.





Financial Statements
Scisparc Ltd's IV. Quarter Investments $ 5 Millions SPRC's Balance sheet
Scisparc Ltd's IV. Quarter Income $ 13 Millions Quarterly SPRC's Income Statement
SPRC's Income by Division See SPRC's Income by Division


SPRC Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 5 9 10 6 8
Y / Y Investment Growth -39.94 % -6.76 % 48.66 % -20.96 % 470.56 %
Net Income in Millions 13 -7 -6 -3 -6
Y / Y Net Income Growth - - - - -
Annual Return On Investment 234.01 % -83.59 % -61.36 % -40.19 % -70.95 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 234.01 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SPRC's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SPRC's Competitors
Subscribers only: Roi for Scisparc Ltd's Suppliers
Subscribers only: Return On Investment for SPRC's Customers

Other Ratios
SPRC's Roa SPRC's Inventory Turnover Ratio SPRC's Growth Rates SPRC's Dividend Statistics
SPRC's Profitability Ratios SPRC's Asset Turnover Ratio SPRC's Dividend Growth
SPRC's Roe SPRC's Valuation Ratios SPRC's Financial Strength Ratios SPRC's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Glucotrack Inc   372.04 %
Elutia Inc   358.27 %
Oncotelic Therapeutics Inc   252.91 %
Atara Biotherapeutics Inc   242.55 %
Traws Pharma inc   234.73 %
Scisparc Ltd  234.01 %
Petros Pharmaceuticals inc   233.39 %
Omada Health Inc   200.69 %
Interpace Biosciences Inc   198.59 %
Rigel Pharmaceuticals Inc  185.38 %
Icecure Medical Ltd  166.12 %
Silexion Therapeutics Corp  142.64 %
Heartflow Inc   142.09 %
Capforce Inc   140.91 %
Check Cap Ltd  120.45 %
Coherus Oncology inc   119.44 %
Kyntra Bio Inc   118.89 %
Lifemd Inc   105.75 %
Biocryst Pharmaceuticals Inc   88.36 %
Advanced Biomed Inc.  84.64 %
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %

Date modified: 2026-07-07T13:49:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.